Formulation Development

Covering a 135,000ft² area, our Miami facility is registered with the FDA and complies fully with current good manufacturing practice (cGMP) guidelines. It has the capacity for R&D, process development and small-scale launches, including pilot-scale cGMP manufacturing and packaging to support pilot pharmac...

Avéma Pharma Solutions and PL Developments has responded to the increasing demand for gummies by adding gummy manufacturing capabilities, including a small line for R&D and scale up, as well as four additional commercial lines with an anticipated capacity of 1.2bn gummies annually. Commercially available p...

Avéma has a full analytical lab, staffed by experienced professionals with more than 200 years of method development and validation experience.

Avéma can help you improve patient compliance with innovative packaging solutions for solid and liquid dose productions. Our facilities offer flexibility to accommodate run size and interchangeable tooling for line flexibility and cost efficiency – so, we can provide support for all products at all stages ...

To ensure the seamless transition from pilot manufacturing, Avéma starts with small-scale production equipment in the development process that has identical operational attributes to what will be used in full-scale commercial manufacturing all under the supervision of a single project manager to ensure tha...

Avéma Pharma Solutions can help guide your product successfully through NDA, ANDA, CBE 30 and 505(b)(2) filings with the FDA.

From OTC and Rx to diagnostics and dietary supplements, Avéma manufactures a full range of solid and liquid dose products, all manufactured under strict FDA guidelines and cGMP compliance. With an ever-growing portfolio of innovative formulas and a diverse mix of state-of-the-art equipment, our offerings a...

Avéma offers formulation, process and analytical development support of new or existing products using the most current and effective active ingredients and delivery systems. Our team of scientists bring decades of pre-formulation development expertise to your products, combined with the knowledge of how t...

As part of its commitment to full service support, Avéma Contract Services is pleased to offer our customers support with ANDA and NDA applications, including bio equivalency studies, collecting background data, supervising technology tranfers and reviewing applications to make sure that companies com...

Lessons Learned: Choosing & Managing a CDMOAvéma Pharma Solutions, a division of PL Developments (PLD), is in the unique position being both a consumer and supplier of global CDMO services for both OTC and rX products. In this presentation, we’ll explore the lessons we have learned from managing our own CMOs that have allowed us to build a better CDMO model for our Avéma customers. We’ll address the areas that can help speed up your time-to-market, keep development costs under control, and smooth the FDA approval and commercial launch process. Watch our webinar at https://app.webinar.net/K2OlZE6JLx9?mcc=WebsitePost

The global gummy vitamin market is expected to reach 10.6 billion by 2025 and gummies are gaining traction as a drug delivery system -- especially for children and seniors who resist taking pills, capsules and liquids. Mitchell Slade, who brings more than 20 years of gummy manufacturing experience at Nature’s Bounty to the table, will address the challenges of developing gummies beyond supplements, such ensuring consistent dosage, production and taste. Avéma/PLD has a world-class GDUFA facility that is CFR 211 and CFR 111 certified, uses a starchless gummy manufacturing process and brings 40+ years of formulating experience to the development of innovative drug delivery systems.

The global gummy vitamin market is expected to reach 10.6 billion by 2025 and gummies are gaining traction as a drug delivery system -- especially for children and seniors who resist taking pills, capsules and liquids. Mitchell Slade, who brings more than 20 years of gummy manufacturing experience at Nature’s Bounty to the table, will address the challenges of developing gummies beyond supplements, such ensuring consistent dosage, production and taste. Avéma/PLD has a world-class GDUFA facility that is CFR 211 and CFR 111 certified, uses a starchless gummy manufacturing process and brings 40+ years of formulating experience to the development of innovative drug delivery systems.